PRODUCT NEWS | DEPARTMENTS
ATZUMI NASAL POWDER APPROVED FOR ACUTE MIGRAINE RELIEF
PENPULIMAB APPROVED FOR RARE HEAD AND NECK CANCER
The FDA has approved Atzumi , a novel nasal powder formulation of dihydroer- gotamine mesylate, for the acute treat- ment of migraine in adults. This new option offers a needle-free, fast-act - ing alternative for patients who need rapid symptom relief—especially those who experience nausea and cannot toler- ate oral medications. Its ease of admin- istration and portability may improve adherence for patients prone to sudden migraine attacks.
The FDA has greenlit penpu- limab-kcqx, a PD-1 blocking mono- clonal antibody, for the treatment of advanced nasopharyngeal carci- noma , a rare form of head and neck cancer. As a checkpoint inhibitor, penpu- limab adds another tool to the growing arsenal of precision immunotherapies. Its approval provides hope for patients who often have limited treatment options and face poor prognoses.
JOBEVNE BECOMES LATEST BEVACIZUMAB BIOSIMILAR FOR CANCER THERAPY
Jobevne (bevacizumab-nwgd) has been approved by the FDA as a biosimilar to Avastin, indicated for a variety of cancers including col- orectal, non-small cell lung, and glio- blastoma. With the rising demand for oncology cost-containment strategies, Jobevne offers a more affordable alternative without compromising clinical efficacy. Pharmacy teams in both hospital and specialty settings will likely see it added to formularies soon. method is designed for patients who struggle with traditional tablets or need discreet, convenient dosing. The film dissolves quickly without water, expanding treatment options in both inpatient and outpatient mental health settings.
VANRAFIA APPROVED FOR IGA NEPHROPATHY WITH HIGH RISK OF PROGRESSION Vanrafia (atrasentan) received FDA approval in April 2025 for reducing pro- teinuria in adults with primary immu- noglobulin A nephropathy (IgAN) who are at risk for rapid disease progres- sion. As a selective endothelin receptor antagonist, Vanrafia targets a key path- way involved in kidney inflammation and fibrosis. This approval marks an important step forward in managing a condition that frequently leads to end- stage renal disease.
MEZOFY ORAL FILM OFFERS NEW OPTION FOR SCHIZOPHRENIA PATIENTS In April 2025, the FDA approved Mezofy , an oral film formulation of aripiprazole, for the treatment of schizo- phrenia in adults and adolescents aged 13 and older. This new delivery
CPhTCONNECT.COM | 7
Made with FlippingBook - PDF hosting